The #PrEP4All campaign made the call for affordable pre-exposure prophylaxis a national news story.
Activists and doctors say they're ready to go further if Gilead won't agree to -- or the U.S. government won't force -- a price reduction to make PrEP accessible to more Americans who need it.
Advocates say the price is a step in the right direction. But does it go far enough?
But a survey reveals that about a third of black and Latino gay men would be willing to pay more than $50 per month for a prescription.
In a debate during a plenary session, Michael Saag, M.D., argued for more activism to make PrEP accessible to people who need it.
Drug pricing expert Tim Horn helps us make sense of the administration's future plans for the Medicare Part D and 340B programs.
In order to adequately address the HIV epidemic in the United States, two advocates argue that the high cost of antiretroviral drugs must be addressed.
Patients' rights activists and health industry's big players are usually at odds with each other, but now they are championing similar tactics to tame prescription drug prices.
Despite the tremendous success of the program -- or perhaps because of it -- and courtesy of a substantial lobbying push from the Pharmaceutical Research and Manufacturers of America (PhRMA), the 340B program has found itself under close scrutiny by ...
A federal drug pricing program that most Americans have never heard of has caused an all-out scrum between the big pharmaceutical and hospital lobbies, with Ryan White clinics and community health centers caught in the tussle.